Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2017-01-03 Capital/Financing Update
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release titled 'RedHill Biopharma Announces Exercise of Underwriters' Option'. The document is short (1873 characters) and primarily serves as an announcement of a financing event (exercise of underwriters' option). There are no detailed financial statements or comprehensive financial data presented. The content relates to a capital raising or financing update rather than a full report or earnings release. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2017-01-03 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about a co-promotion agreement but does not contain detailed financial statements or comprehensive report data. The document length is short (1913 characters), and it primarily serves as a regulatory announcement of a corporate event rather than a full financial report or detailed management discussion. According to the rules, Form 6-K filings are typically regulatory filings for foreign issuers to report material events and are classified under Regulatory Filings (RNS).
2017-01-03 English
SC 13G
Major Shareholding Notification
2016-12-29 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to SEC rules. It includes a press release about a presentation at a biotech showcase. The document is short (1870 characters) and primarily serves as an announcement of an event rather than containing detailed financial data or comprehensive reports. Form 6-K filings are typically used for current reports by foreign private issuers and often contain press releases or other material information. Given the nature and length of the document, it does not qualify as an Annual Report (10-K), Interim Report (IR), or other detailed financial filings. It is best classified under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-12-28 English
FORM 6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about the closing of a public offering and registered direct offering of shares and warrants. The document is short (2006 characters) and primarily announces a financing event. It does not contain detailed financial statements or comprehensive financial analysis. The content focuses on capital raising activities, which aligns with Capital/Financing Update filings. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-12-27 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by RedHill Biopharma Ltd. It details the offering of American Depositary Shares and warrants, underwriting discounts, use of proceeds, risk factors, and other offering-specific information. This type of document is a capital raising disclosure, not a financial report, earnings release, or management discussion. It is a detailed disclosure related to financing activities and capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to clear identification of offering terms and regulatory references to Rule 424(b)(5).
2016-12-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.